JPH05228128A - Capsule for medical treatment - Google Patents

Capsule for medical treatment

Info

Publication number
JPH05228128A
JPH05228128A JP3753192A JP3753192A JPH05228128A JP H05228128 A JPH05228128 A JP H05228128A JP 3753192 A JP3753192 A JP 3753192A JP 3753192 A JP3753192 A JP 3753192A JP H05228128 A JPH05228128 A JP H05228128A
Authority
JP
Japan
Prior art keywords
liquid crystal
capsule
body
gel actuator
crystal gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP3753192A
Other languages
Japanese (ja)
Inventor
Isami Hirao
Yorio Matsui
Hiroki Moriyama
Mitsugi Nagayoshi
勇実 平尾
頼夫 松井
宏樹 森山
貢 永吉
Original Assignee
Olympus Optical Co Ltd
オリンパス光学工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olympus Optical Co Ltd, オリンパス光学工業株式会社 filed Critical Olympus Optical Co Ltd
Priority to JP3753192A priority Critical patent/JPH05228128A/en
Publication of JPH05228128A publication Critical patent/JPH05228128A/en
Application status is Withdrawn legal-status Critical

Links

Abstract

PURPOSE: To provide the capsule for medical treatment which has good responsiveness, can draw the bodily fluid from a desired section and dose drugs to this part and is safe to the human body.
CONSTITUTION: This capsule is constituted by providing a reservoir 2 housing the drugs, the bodily fluid, etc., a liquid crystal gel actuator 3 for changing the volume of this reservoir 2 and a switching circuit 8 for controlling the operation of this liquid crystal gel actuator 3 within a capsule body 1.
COPYRIGHT: (C)1993,JPO&Japio

Description

【発明の詳細な説明】 DETAILED DESCRIPTION OF THE INVENTION

【0001】 [0001]

【産業上の利用分野】本発明は、生体の体腔内に投与する医療用カプセルに関する。 The present invention relates to a medical capsule to be administered into a body cavity of a living body.

【0002】 [0002]

【従来の技術】これまで、生体の体腔内への薬剤放出、 BACKGROUND OF THE INVENTION In the past, drug release into the body cavity of a living body,
体液採取が任意の時に電気制御できる医療用カプセルは、例えば特開平2−19140号公報に示されている。 Medical capsule body fluid collection can be electrically controlled at any time, for example is shown in Japanese Patent Laid-Open No. 2-19140. また特開平2−19140号公報にはPH値に基づき、または、電圧を印加することによって膨張して体積が増加するメカノケミカル物質を使用した医療用カプセルが示されている。 Also in JP-A-2-19140 based on PH value, or, is a medical capsule volume inflated using mechanochemical substances which increase by applying a voltage is illustrated. この医療用カプセルによれば、カプセル内でメカノケミカル物質の容積を変化させることにより収納室の薬液を放出しようとするものである。 According to the medical capsule, it is intended to release the drug solution storage chamber by varying the volume of the mechanochemical substance in the capsule.

【0003】 [0003]

【発明が解決しようとする課題】ところで、前述した医療用カプセルでは、医療用カプセルの薬液の収納室の容積を変化させる手段としてメカノケミカル物質を用いたが、メカノケミカル物質は応答性に劣るので、目的の部位を通り過ぎてしまってから体液の採取や薬剤の投与がおこなわれたり、所望の部位で体液の採取や薬剤の投与を確実に行うことは難しい。 [SUMMARY OF THE INVENTION] In the medical capsule described above, was used mechanochemical material as a means for changing the volume of the housing chamber of the chemical liquid medical capsule, since mechanochemical material is inferior in responsiveness , or is made administration of body fluids collected and drugs from gone past the site of interest, it is difficult to reliably perform the administration of the body fluid sampling and drug at the desired site.

【0004】また、形状記憶合金を用いた医療用カプセルも考えられるが形状記憶合金は、体温以上に発熱させることで変形するものなので人体に熱的影響を及ぼすという問題がある。 [0004] The medical capsule is also considered the shape memory alloy with a shape memory alloy has a problem in that the thermal influence on the human body because they are being deformed by generating heat above body temperature.

【0005】本発明は前記事情に着目してなされたもので、その目的とするところは、応答性が良く、所望の部位への体液の採取、薬剤の投与ができ、かつ人体に対して安全な医療用カプセルを提供することにある。 [0005] The present invention has been made in view of the above circumstances, it is an object of good responsiveness, collected body fluid to a desired site, can be administration of a drug, and safe to the human body and to provide a a medical capsule.

【0006】 [0006]

【課題を解決するための手段】この発明の医療用カプセルは、前記目的を達成するために、薬剤・体液等を収容する収納室と、この収納室の容積を変化させる手段とを有し、この収納室の容積を変化させる手段を液晶ゲルアクチュエータと、この液晶ゲルアクチュエータの作動を制御する手段とで構成したことを特徴とする。 Means for Solving the Problems] medical capsule of the present invention, in order to achieve the object, comprising: a storage chamber for containing medicament, such as body fluid, and means for varying the volume of the storage chamber, It means a liquid crystal gel actuator for varying the volume of the storage chamber, characterized by being constituted by a means for controlling the operation of the liquid crystal gel actuator.

【0007】 [0007]

【作用】前記構成の医療用カプセルによれば、液晶ゲルアクチュエータの高分子液晶の両端に電極を設け、それらの電極間に液晶ゲルアクチュエータの作動を制御する手段により電圧を印加すると、電極方向に収縮し、医療用カプセルの薬剤・体液等を収納する収納室の容積を変化させることにより、所望の部位に薬液を投与したり、 SUMMARY OF] According to the medical capsule of the configuration, the electrodes provided at both ends of the polymer liquid crystal of the liquid crystal gel actuator, when voltage is applied by means for controlling the operation of the liquid crystal gel actuator between the electrodes, the electrode direction contracted, by changing the storage chamber volume for containing the medicament, body fluid or the like of the medical capsule, or administered a drug solution at the desired site,
所望の位置の体液を採取することができるようになる。 It is possible to collect a body fluid of a desired position.

【0008】 [0008]

【実施例】以下、本発明の医療用カプセルの各実施例を図面に基づいて説明する。 BRIEF DESCRIPTION based on the embodiments of the medical capsule of the present invention with reference to the drawings.

【0009】図1及び図2は第1の実施例を示し、1は生体に対して無害な材料によって円筒形に形成されたカプセル本体で、2は薬剤や体液を収容する収納室としてのリザーバである。 [0009] Figures 1 and 2 show a first embodiment, 1 is a capsule body which is cylindrically formed by a harmless material to a living body, 2 is a reservoir of a housing chamber containing medicament and body fluids it is. このリザーバ2の容積を変化させ、 The volume of the reservoir 2 is changed,
薬剤を投与したり体液を収容したりする手段は、液晶ゲルアクチュエータ3と、この液晶ゲルアクチュエータ3 Means or accommodating the body fluid or administration of drugs, a liquid crystal gel actuator 3, the liquid crystal gel actuator 3
の作動を制御する制御部4とから構成されている。 And a control unit 4 which controls the operation. この液晶ゲルアクチュエータ3と制御部4は仕切り板5により区分けされている。 The liquid crystal gel actuator 3 and the control unit 4 is divided by a partition plate 5.

【0010】前記液晶ゲルアクチュエータ3は、高分子液晶の両端に電極を設け、それらの電極間に電圧を印加すると電極方向に収縮し、電圧除去によって戻る電歪型アクチュエータを伸縮方向に積層することにより構成されている。 [0010] The liquid crystal gel actuator 3, the electrodes provided at both ends of the polymer liquid crystal, contracts voltage to the electrode direction is applied to between the electrodes, stacking the back electrostrictive actuator by voltage removal stretch direction and it is made of. この液晶ゲルアクチュエータ3はある程度長い時間通電しても高い熱や水素ガスを発生することがないので人体に対し安全となっている。 And it has a safety to the human body because the liquid crystal gel actuator 3 is not able to generate high heat and hydrogen gas be energized relatively long time.

【0011】なお、液晶ゲルアクチュエータ3の材料としては、例えば側鎖型高分子液晶で側鎖に強誘電性のメソゲン基を含む構造のもので、主鎖にポリシロキサン、 [0011] As a material of the liquid crystal gel actuator 3, for example, those with a side chain polymeric liquid crystal structure containing a ferroelectric mesogenic group in the side chain, main chain polysiloxane,
ポリブタジエン、ポリエチレン構造等を有する高分子液晶又はそれらを架橋によりエラストマー化した液晶エラストマー等により構成されている。 Polybutadiene, a liquid crystal elastomer or the like elastomer by crosslinking a polymer liquid crystal or their having a polyethylene structure and the like.

【0012】リザーバ2とカプセル本体1との接続部においては、そのリザーバ2を外部に連通する連通路としての連通孔6が形成されている。 [0012] In the connecting portion between the reservoir 2 and the capsule body 1, communicating holes 6 of the communication passage for communicating the reservoir 2 to the outside is formed. また、制御部4にはエネルギ源としてのバッテリ7とこの液晶ゲルアクチュエータ3の作動を制御する手段としてのスイッチング回路8と、外部からの信号を受信するアンテナ9及び受信回路10が設けられている。 Further, the control unit 4 and the switching circuit 8 as a means for controlling the operation of the liquid crystal gel actuator 3 and the battery 7 as an energy source, the antenna 9 and the receiving circuit 10 receives a signal from the outside is provided .

【0013】前記アンテナ9は受信回路10に接続され、受信回路10は前記スイッチング回路8に電気的に接続されている。 [0013] The antenna 9 is connected to the receiving circuit 10, receiving circuit 10 is electrically connected to the switching circuit 8. また、スイッチング回路8はバッテリ7に電気的に接続されている。 The switching circuit 8 is electrically connected to the battery 7.

【0014】また、液晶ゲルアクチュエータ3の軸方向の両端の電極のうち、リザーバ2に取付けられている側の電極はバッテリ7に、仕切り板5に取付けられている側の電極はスイッチング回路8に電気的に接続されている。 Further, among the both axial ends of the electrodes of the liquid crystal gel actuator 3, the electrode on the side attached to the reservoir 2 to the battery 7, the side of the electrode attached to the partition plate 5 to the switching circuit 8 It is electrically connected. なお、カプセル本体1の表面にはX線で透視できるように造影剤がコーティングされている。 Incidentally, the contrast agent is coated to the surface of the capsule body 1 can fluoroscopic X-ray.

【0015】このように構成された第1の実施例の医療用カプセルを例えば腸液採取用として用いると、図1 [0015] With the medical capsule of the first embodiment thus configured as, for example, for intestinal fluid collecting, 1
(a)に示すように、医療用カプセルは、非通電時の状態ではリザーバ2の中には何も入っていない。 (A), the medical capsule is nothing enters Among the reservoir 2 is in the non-energized state. この状態で医療用カプセルを生体の体外から経口投与する。 Orally administered medical capsule from outside of the living body in this state. この医療用カプセルが小腸に達したと思われる時間に体外から電波を発信すると、アンテナ9を通して受信回路10 If the medical capsule is transmits radio waves from outside the body to the time seems to have reached the small intestine, it received through the antenna 9 circuit 10
が受信すると、スイッチング回路8がオン状態となり、 There receives, the switching circuit 8 is turned on,
バッテリ7の電圧を液晶ゲルアクチュータ3に印加する。 Applying a voltage of the battery 7 to the liquid crystal gel accession tutor 3. すると液晶ゲルアクチュエータ3は軸方向に収縮する。 Then the liquid crystal gel actuator 3 contracts in the axial direction. その時、リザーバ2の容積を広げるので、図1 Then, since expanding the volume of the reservoir 2, FIG. 1
(b)に示すように連通孔6を通じて腸液11を採取する。 Collecting intestinal fluid 11 through the communication hole 6 as shown in (b).

【0016】なお、電波を送るタイミングとして、カプセル本体1に影像剤が塗られていればX線により腸液を採取したい部位を確認してもよいし、体外から超音波を当てて医療用カプセル位置を確認してもよい。 [0016] Incidentally, as a timing for sending a radio wave may be sure site to be collected intestinal fluid by X-ray if imaging agent is painted capsule body 1, a medical capsule position against the ultrasonic waves from outside the body You may be sure.

【0017】したがって、この医療用カプセルは、体液の採取を任意の時に速やかに体外からの発信により制御できる。 [0017] Accordingly, the medical capsule, the collection of the body fluid can be controlled by the transmission from rapidly from the body at any time. しかも通電時に高い熱や水素ガス等を発生することがないので、人体に安全である。 Moreover, since there is no possible to generate a high heat and hydrogen gas or the like at the time of energization, it is safe to the human body.

【0018】また、本実施例では体液として腸液を採取したが、他の体液でも採取することができる。 Further, in the present embodiment has been collected intestinal fluid as a body fluid, it can also be collected in other body fluids. さらに非通電時は図1(b)に示す状態とし、予め薬剤をリザーバ2内に収めた状態とし、この状態で通電して図1 Further when not energized is the state shown in FIG. 1 (b), a state of matches and advance drug into the reservoir 2, FIG. 1 by energizing in this state
(a)に示すように液晶ゲルアクチュエータ3を膨張させて、リザーバ2を収縮させることにより任意の時にしかも体外からの発信によりリザーバ2内に収納された薬剤を所望部位に投与できる。 Inflating the liquid crystal gel actuator 3 (a), the drug accommodated in the reservoir 2 by the transmission from the addition outside at any time by contracting the reservoir 2 can be administered to the desired site.

【0019】本発明の第2の実施例を図2に示し説明する。 [0019] The second embodiment of the present invention shown will be described in FIG. 第2の実施例の構成は前記制御部4を除いては第1 The configuration of the second embodiment except for the control unit 4 first
の実施例と同じである。 Is the same as that of Example. なお、第1の実施例に示した構成と重複するものには同一符号を付して説明を省略する。 Note that those overlapping with the configuration shown in the first embodiment will not be described are denoted by the same reference numerals.

【0020】本実施例の制御部14は、バッテリ7の他に液晶ゲルアクチュエータ3の作動を制御する手段としてスイッチ端子15が設けられている。 The control unit 14 of the present embodiment, the switch terminal 15 is provided as a means for controlling the operation of the liquid crystal gel actuator 3 in addition to the battery 7. またスイッチ端子15とカプセル本体1との接合部にはカプセル本体1 The capsule body 1 is at the junction of the switch terminal 15 and the capsule body 1
の壁の一部に孔16が開けられており、その孔16は消化膜17によって塞がれている。 Of which a hole 16 opened in part of the wall, the hole 16 is closed by digestion film 17.

【0021】この消化膜17は、例えば脂肪酸膜のように高いPH値を感知して溶けるタイプのものや、腸内細菌に反応して溶けるもので構成されている。 [0021] The digestion film 17, for example of those or type soluble senses the high PH value as fatty film, and a ones soluble in response to intestinal bacteria. また、前記スイッチ端子15は2つの絶縁状態にある端子15a, Also, the terminal 15a switch terminal 15 is located in the two insulated,
15bによって構成されている。 It is constituted by 15b.

【0022】このように構成された医療用カプセルによれば、経口投与するところまでは第1の実施例と同様である。 According to the thus constructed medical capsule, to the point where oral administration is the same as in the first embodiment. 消化膜17が例えば脂肪酸膜のように高いPH値に反応して溶けるタイプのものであれば、医療用カプセルが小腸に達すると、小腸内はアルカリ性であるから消化膜17がそれに反応して溶ける。 As long as the type soluble in response to the high PH value as digestive film 17 such as fatty acid film, the medical capsule reaches the small intestine, the small intestine dissolves in response to it digested film 17 because it is alkaline . (胃液は強い酸性であるから消化膜17は反応しない。)すると体液がスイッチ端子15内に入る。 (Gastric digestion film 17 because it is strongly acidic will not react.) Then the body fluid enters the switch terminal 15. 最初は絶縁状態であった端子1 First terminal 1 was insulated
5a,15bが体液を介して電気的に通じ、バッテリ7 5a, 15b is electrical communication through the fluid, the battery 7
の電圧が液晶ゲルアクチュエータ3に印加される。 Voltage is applied to the liquid crystal gel actuator 3. その後の体積採取作用は前述した第1の実施例と同様である。 After that the volume taken action is the same as the first embodiment described above. さらに、第1の実施例の作用・効果に加えて、体外から信号を発信しなくとも、体内において適当な部位で体液を自動的に速やかに採取できる。 Furthermore, in addition to the operation and effect of the first embodiment, even without transmitting a signal from outside the body, body fluid can be automatically rapidly taken at an appropriate site in the body.

【0023】また、予め薬剤をリザーバ2内に収めた状態とし、所望部位に達した時に消化膜17が解けてリザーバ2に収納された薬剤が投与されるように用いることもできる。 Further, pre-drug and the state of matches in the reservoir 2, the drug accommodated in the reservoir 2 by digestion film 17 melts when reaching the desired site may be used to be administered.

【0024】本発明の第3の実施例を図3(a)(b) [0024] A third embodiment of the present invention FIG. 3 (a) (b)
に示す。 To show. 本実施例における医療用カプセルは、生体に無害な材料によってコーティングされた積層型の液晶ゲルアクチュエータ20と、それを動作させるための制御室21及び制御部壁22、それらの接合部として隔壁23 Medical capsule in the present embodiment, the control chamber 21 and the control wall 22 for the liquid crystal gel actuator 20 of the multilayer coated by harmless materials in vivo, to operate it, the partition wall 23 as their joint
とで構成されている。 It is composed of a.

【0025】また、液晶ゲルアクチュエータ20は、軸周囲がくり抜かれたドーナツ形をしており、そのくりぬかれた部分には芯棒25が設けられている。 Further, the liquid crystal gel actuator 20 has a donut-shaped about the axis is hollowed out, the core rod 25 is provided at the hollowed portions. 液晶ゲルアクチュエータ20と芯棒25の一端はそれぞれ隔壁23 Each one end of the liquid crystal gel actuator 20 and core rod 25 partition wall 23
に取付けているが、他端は図3(a)に示すように非通電時には液晶ゲルアクチュエータ20の方が芯棒25より長くなっているために、薬剤26を収納する薬剤収納室27が形成されている。 Although attached, to the other end at the time of non-energization, as shown in FIG. 3 (a) towards the liquid crystal gel actuator 20 is longer than the core rod 25, the chemical accommodating chamber 27 for accommodating a drug 26 is formed It is. また、薬剤26が薬剤収納室27から漏れないように、薬剤収納室27が外部と連通する部分には蓋としての薄膜28が設けられている。 In addition, as the drug 26 from leaking from the drug storage chamber 27, the portions chemical accommodating chamber 27 is communicated with the external film 28 is provided as a lid.

【0026】また、制御室21の中にはエネルギ源としてのバッテリ30と、スイッチング回路31と、外部からの信号を受信するアンテナ32及び受信回路33が設けられている。 Further, a battery 30 as an energy source in the control room 21, a switching circuit 31, the antenna 32 and the receiving circuit 33 that receives a signal from the outside. 前記アンテナ32は受信回路33に電気的に接続され、受信回路33はスイッチング回路31に電気的に接続されている。 The antenna 32 is electrically connected to the receiving circuit 33, receiving circuit 33 is electrically connected to the switching circuit 31. また、スイッチング回路31 The switching circuit 31
はバッテリ30に電気的に接続されている。 It is electrically connected to the battery 30. 液晶ゲルアクチュエータ20の両端の電極のうち、片方はバッテリ30に、もう片方はスイッチング回路31に電気的に接続されている。 Of both ends of the electrodes of the liquid crystal gel actuator 20, one in the battery 30, the other is electrically connected to the switching circuit 31. なお、このカプセルの表面にはX線で透視できる用に造影剤がコーティングされていてもよい。 Incidentally, the contrast agent in use on the surface of the capsules can be fluoroscopic X-ray may be coated.

【0027】このように構成された医療用カプセルを例えば薬剤放出用とした場合は、図3(a)に示すように非通電時の状態では薬剤収納室27の中に薬剤26が収納されている。 [0027] If the thus configured for a medical capsule for example drug release, and the drug 26 is housed inside of the medicine container chamber 27 in the state at the time of non-energization, as shown in FIG. 3 (a) there.

【0028】この状態でまず、医療用カプセルを経口投与する。 [0028] First, in this state, the medical capsule is administered orally. 仮りに薬剤26を小腸に投与したい場合は、この医療用カプセルが小腸に達したと思われる時間に体外から電波を発信する。 If you wish to administer the drug 26 into the small intestine for temporary, the medical capsule is transmits radio waves from outside the body to the time seems to have reached the small intestine. これをアンテナ32を通して受信回路33が受信するとスイッチング回路31がオン状態となり、バッテリ30の電圧を液晶ゲルアクチュエータ20に印加する。 This switching circuit 31 receives the reception circuit 33 through the antenna 32 is turned on to apply the voltage of the battery 30 to the liquid crystal gel actuator 20. これによって液晶ゲルアクチュエータ20は軸方向に収縮する。 This liquid crystal gel actuator 20 contracts in the axial direction. その時に、芯棒25は変化しないので薬剤26は芯棒25の端面に押されて薄膜28 At that time, the core rod 25 does not change agent 26 is pushed to the end surface of the core rod 25 thin film 28
を破って図3(b)のようにカプセル外に放出される。 Beating is released into the capsule out as in FIG. 3 (b).
従って液晶ゲルアクチュエータ20が収縮して薬剤26 Therefore in the liquid crystal gel actuator 20 contracted agents 26
が放出された時、薬剤収納室27と薄膜28はほぼ消滅した状態となっている。 When but was released chemical accommodating chamber 27 and the film 28 it is almost disappeared state.

【0029】また、電波を送るタイミングとしてカプセル表面に造影剤がコーティングされていればX線により薬剤を放出したい部位を確認してもよいし、体外から超音波を当ててカプセル位置を確認してもよい。 Further, it may be confirmed region to be released drug by X-ray if contrast agents the capsule surface as the timing for sending radio waves if coated, to check the capsule position against the ultrasonic waves from outside the body it may be.

【0030】したがって、医療用カプセルからの薬剤2 [0030] Accordingly, agents 2 from the medical capsule
6の放出を任意の時に速やかに体外からの発信により制御できる。 6 release can be controlled by transmission from rapidly from the body at any time. しかも通電時に高い熱や水素ガス等を発生することができないので、人体に安全である。 Moreover it is not possible to generate high heat and hydrogen gas or the like at the time of energization, it is safe to the human body. なお、前述した第1,2,3の実施例においては、いずれの場合も電圧印加により収縮する液晶ゲルアクチュエータを用いたが本アクチュエータを電圧印加により膨張する液晶ゲルアクチュエータを用い、それによって薬剤収納室27 In the first, second and third embodiments described above, but using a liquid crystal gel actuator contracts by the voltage application cases using a liquid crystal gel actuator expands by applying voltage to the actuator, whereby the medicine container room 27
の容積を変化されるようにしてもよい。 It may be the change in volume.

【0031】本発明の第4の実施例を図4乃至図6に従って説明する。 [0031] illustrating a fourth embodiment of the present invention according to FIGS. 4 to 6. 本実施例においては、コイル状の液晶ゲルアクチュエータ40を用いる。 In this embodiment, a coiled liquid crystal gel actuator 40. このコイル状の液晶ゲルアクチュエータ40の両端には図4に示すように電極41,42が設けられ、それぞれにリード線43,44 This is the opposite ends of the coiled liquid crystal gel actuator 40 electrodes 41 and 42 are provided as shown in FIG. 4, lead wires respectively 43 and 44
が接続されている。 There has been connected.

【0032】また、図5(a)に示すように本実施例における医療用カプセル50は、回転蓋51と薬剤収容室52と制御室53とからなりいずれも円筒形状に形成されている。 Further, medical capsule 50 in the embodiment as shown in FIG. 5 (a), both made from the rotating lid 51 and the drug accommodating chamber 52 and control chamber 53 is formed in a cylindrical shape. 薬剤収容室52の周囲にはコイル状の前記液晶ゲルアクチュエータ40が設けられ、その一端は回転蓋51に、他端は制御室53に固定されている。 The liquid crystal gel actuator 40 coiled around the drug accommodating chamber 52 is provided, one end of the rotating lid 51 and the other end fixed to the control chamber 53. 薬剤収容室52は制御室53に固定されている。 Medicine accommodating chamber 52 is fixed to the control chamber 53.

【0033】コイル状の液晶ゲルアクチュエータ40はその自然長よりも長くなるように引き伸ばした状態で回転蓋51と制御室53に固定されているため、回転蓋5 [0033] Since the coiled liquid crystal gel actuator 40 which is fixed to the rotary cover 51 and the control chamber 53 in a state stretched to be longer than its natural length, rotating the cover 5
1はコイル状の液晶ゲルアクチュエータ40の付勢力によって薬剤収容室52と接触保持されている。 1 is held in contact with the chemical-receiving chamber 52 by the biasing force of the coiled liquid crystal gel actuator 40.

【0034】図5(b)はカプセル正面から回転蓋51 [0034] FIG. 5 (b) rotating the capsule front lid 51
を見た図である。 It is a view of the. 回転蓋51には連通孔54が設けられ、ゴム等の弾性に富んだ弾性部材55,56,57が埋め込んである。 A rotary lid 51 is provided communicating hole 54, an embedded elastic members 55, 56, 57 rich elasticity such as rubber. また薬剤収容室52にも前記弾性部材55,56,57に対応した位置に放出孔58,59, The release at a position corresponding to the elastic member 55, 56 and 57 to the chemical-receiving chamber 52 holes 58, 59,
60が設けられている。 60 is provided.

【0035】また、薬剤収容室52の内側にはそれぞれの放出孔58,59,60にラテックス等の弾性に非常に富んだ材質からなる薄膜リザーバ61a,61b,6 Further, it consists very rich material to the respective discharge holes 58, 59, 60 in the elasticity of the latex inside the chemical-receiving chamber 52 thin reservoir 61a, 61b, 6
1cが設けられている。 1c is provided. (図5(a)で図示されているのは薄膜リザーバ61a,61b) (FIG. 5 (a) thin film reservoir 61a Illustrated by, 61b)

【0036】一方、制御室53の中にはバッテリ63とスイッチング回路64と、アンテナ65及び受信回路6 On the other hand, the battery 63 and the switching circuit 64 into the control chamber 53, the antenna 65 and the receiving circuit 6
6が設けられている。 6 is provided. アンテナ65は受信回路66に電気的に接続され、受信回路66はスイッチング回路64 Antenna 65 is electrically connected to the receiving circuit 66, receiving circuit 66 is a switching circuit 64
に電気的に接続されている。 It is electrically connected to. スイッチング回路64はバッテリ63にそれぞれ電気的につながっている。 The switching circuit 64 is connected to electrical respective battery 63. また、 Also,
リード線44はバッテリ63に、リード線43はスイッチング回路64に電気的に接続されている。 Lead 44 to the battery 63, the lead wire 43 is electrically connected to the switching circuit 64.

【0037】このように構成された医療用カプセルによれば、まず、薄膜リザーバ61a,61bに薬剤67を注入する。 [0037] According to the thus configured medical capsule, firstly, thin reservoir 61a, to 61b to inject the drug 67. 図5(a)では薄膜リザーバ61aには既に薬剤67が注入されている。 Already agent 67 is injected in FIG. 5 (a) in the thin film reservoir 61a. そこでまず、薄膜リザーバ61aに薬剤67を注入する方法を説明する。 Therefore, first, a method of injecting a drug 67 to the thin film reservoir 61a. まず、注入する薬剤67を注射器に入れ、その注射器の針を弾性部材56に刺し込み、放出孔58から薬剤67を注入する。 First, implantation agent 67 placed in the syringe, insert the the syringe needle into the elastic member 56, to inject drug 67 from the discharge hole 58. 薄膜リザーバ61bは薬剤67が注入されるにつれて膨らむ。 Thin reservoir 61b swells as drug 67 is injected. 注入が終了して注射器を抜き去っても弾性部材56によって水密が保たれ、薬剤67が外部には漏れない。 Injection watertight is maintained by the elastic member 56 be retracted away syringe completed, the agent 67 does not leak to the outside. このようにして、弾性部材55,56,57及び放出孔58,59,60を介して3つの薄膜リザーバ6 In this way, three films reservoir 6 through the elastic member 55, 56, 57 and discharge holes 58, 59, and 60
1a,61b,61cに3種類(同種でもかまわない) 1a, 61b, 61c to three (it may be a same type)
の薬剤67を順次注入する。 In order to inject the drug 67. ここで、例えば3種類の薬剤67を一つは胃に、一つは小腸に、一つは大腸に選択的に投与する場合について述べる。 Here, for example, three types of agents 67, one in the stomach, one in the small intestine, one describes the case of selectively administered to the colon.

【0038】まず、医療用カプセルを経口投与する。 [0038] First of all, a medical capsule for oral administration. 医療用カプセルが胃に到達したら、体外から電波を送る。 When the medical capsule reaches the stomach, it sends radio waves from outside the body.
これをアンテナ65を通して受信回路66が受信すると、スイッチング回路64の第1スイッチがオンになり、バッテリ63の電圧を最大の1/3相当の量で液晶アクチュエータ40に印加する。 Upon receiving the reception circuit 66 through which an antenna 65, a first switch of the switching circuit 64 is turned on, it is applied to the liquid crystal actuator 40 a voltage of the battery 63 in an amount of up to 1/3 equivalent. これによってコイル状の液晶アクチュエータ40は軸回りに回転(図5(b) This liquid crystal actuator 40 coiled by rotation around the axis (see FIG. 5 (b)
の矢印方向に)するようにして収縮する。 To the as arrow direction) contracts.

【0039】したがって、回転蓋51が回転し、連通孔54が放出孔58上に位置するようになる。 [0039] Thus, to rotate the rotary cover 51, the communication hole 54 is so positioned on the release holes 58. すると、薄膜リザーバ61a自身が収縮して内部の薬剤67が胃の中に放出させる。 Then, the inside of the drug 67 is released in the stomach thin reservoir 61a itself is contracted.

【0040】次にカプセルが小腸に達したら、体外から電波を送る。 [0040] When the next capsule reaches the small intestine, send radio waves from outside the body. 今度はスイッチング回路64の第2スイッチがオンになり、バッテリ63の電圧を最大の2/3相当の量で液晶ゲルアクチュエータ40に印加し、回転蓋51をさらに回転させ、連通孔54が放出孔59上に位置するようになる。 Now the second switch of the switching circuit 64 is turned on, a voltage of the battery 63 in an amount of up to 2/3 corresponds to the liquid crystal gel actuator 40 further rotates the rotary cap 51, the communication hole 54 discharge hole It will be located on 59. すると図6に示すように薬剤67が放出孔59、連通孔54を介して小腸内に放出される。 Then the agent 67 as shown in FIG. 6 release holes 59, is released into the small intestine via the communication hole 54.
薬剤67が放出し終わると、薄膜リザーバ61bは図5 When the agent 67 has finished releasing film reservoir 61b Figure 5
(a)に示すように収縮状態となる。 A contracted state as shown in (a). 同様にして大腸においても体外からの電波でスイッチング回路64の第3 Similarly, the third switching circuit 64 in the radio waves from outside the body even in the large intestine
のスイッチがオンとなり、バッテリ63の電圧を最大量で液晶ゲルアクチュエータ40に印加して連通孔54が放出孔60上にくるように回転蓋51を回転させ、薬剤を放出する。 Switch is turned on, the voltage of the battery 63 to rotate the rotary cover 51 to the communication hole 54 is applied to the liquid crystal gel actuator 40 in the greatest amount comes onto a release hole 60, to release the drug. なお、弾性ゲルアクチュエータ40が周方向に変形する量は、小さくても済むので回転蓋51と収容室52の摩擦は無視できる。 The amount that the elastic gel actuator 40 is deformed in the circumferential direction, the friction of the rotating lid 51 and the housing chamber 52 so requires even less is negligible.

【0041】さらに前述した各実施例の効果に加え、数種の薬剤を順次、別々の部位で投与できる効果が得られる。 [0041] Further in addition to the effects of the above-mentioned embodiments, sequentially several drugs, effects that can be administered in separate sites can be obtained. また、アクチュエータをコイル状にしたため、薬剤収納室52のスペースも確保されている。 Moreover, because of the actuator coil, the space of the medicine container chamber 52 is also secured.

【0042】 [0042]

【発明の効果】本発明は、前述の如く構成したから、液晶ゲルアクチュエータにより収納室容積を変化させるようにしたので、ある程度長い時間通電していても、高い熱や有害なガスを発生することがないので、人体に安全で、かつ任意の時に薬剤放出又は体液採取を速やかに行うことが可能である医療用カプセルを提供できる。 According to the present invention, since the configuration as described above, since the vary the storage chamber volume by a liquid crystal gel actuator, even if energized relatively long time, to generate high heat and harmful gases since there is no possible to provide a safe to the human body, and it is possible to quickly perform the drug release or body fluid collected at any time medical capsule.

【図面の簡単な説明】 BRIEF DESCRIPTION OF THE DRAWINGS

【図1】(a)(b)は本発明の第1の実施例の医療用カプセルを示す断面図。 [1] (a) (b) is a sectional view of a medical capsule of the first embodiment of the present invention.

【図2】本発明の第2の実施例の医療用カプセルを示す部分断面図。 Partial cross-sectional view showing the medical capsule of the second embodiment of the present invention; FIG.

【図3】(a)(b)は本発明の第3の実施例の医療用カプセルを示す断面図。 [3] (a) (b) is a sectional view of a medical capsule of the third embodiment of the present invention.

【図4】本発明の第4の実施例を示す弾性ゲルアクチュエータの側面図。 Side view of an elastic gel actuator showing a fourth embodiment of the present invention; FIG.

【図5】(a)は同上実施例の医療用カプセルの断面図、(b)は同上実施例の医療用カプセルの正面図。 5 (a) medical sectional view of the capsule according to the exemplary embodiment, (b) is a front view of a medical capsule according to the exemplary embodiment.

【図6】同上実施例の医療用カプセルの部分断面図。 Figure 6 is a partial cross-sectional view of a medical capsule according to the exemplary embodiment.

【符号の説明】 DESCRIPTION OF SYMBOLS

2,27,52…収納室、3,20,40…液晶ゲルアクチュエータ、8,15,31,64…スイッチング回路。 2,27,52 ... accommodation chamber, 3,20,40 ... liquid crystal gel actuator, 8,15,31,64 ... switching circuit.

フロントページの続き (72)発明者 永吉 貢 東京都渋谷区幡ケ谷2丁目43番2号 オリ ンパス光学工業株式会社内 Of the front page Continued (72) inventor Mitsugu Eikichi, Shibuya-ku, Tokyo Hatagaya 2-chome No. 43 No. 2 Olympus Optical Industry Co., Ltd. in

Claims (1)

    【特許請求の範囲】 [The claims]
  1. 【請求項1】 薬剤・体液等を収容する収納室と、この収納室の容積を変化させる手段とを有する医療用カプセルにおいて、前記収納室の容積を変化させる手段を液晶ゲルアクチュエータと、この液晶ゲルアクチュエータの作動を制御する手段とで構成したことを特徴とする医療用カプセル。 And 1. A storage room containing medicament, body fluid, etc., in medical capsule having a means for changing the volume of the storage chamber, and a liquid crystal gel actuator means for varying the volume of the storage chamber, the liquid crystal medical capsule, characterized in that is constituted by a means for controlling the operation of the gel actuator.
JP3753192A 1992-02-25 1992-02-25 Capsule for medical treatment Withdrawn JPH05228128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3753192A JPH05228128A (en) 1992-02-25 1992-02-25 Capsule for medical treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3753192A JPH05228128A (en) 1992-02-25 1992-02-25 Capsule for medical treatment

Publications (1)

Publication Number Publication Date
JPH05228128A true JPH05228128A (en) 1993-09-07

Family

ID=12500118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3753192A Withdrawn JPH05228128A (en) 1992-02-25 1992-02-25 Capsule for medical treatment

Country Status (1)

Country Link
JP (1) JPH05228128A (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006110193A (en) * 2004-10-15 2006-04-27 Olympus Corp Introduction apparatus into patient, and production method therefor
JP2008280461A (en) * 2007-05-11 2008-11-20 Kagoshima Univ Liquid crystal gel, heat drive unit, and method for producing liquid crystal gel
JP2010509969A (en) * 2006-11-21 2010-04-02 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Drug delivery devices, capsules, and drug delivery or diagnostic system for invivo
JP2010524512A (en) * 2007-02-01 2010-07-22 プロテウス バイオメディカル インコーポレイテッド Ingestible event marker system
JP2012183385A (en) * 2005-04-28 2012-09-27 Proteus Biomedical Inc Pharma-informatics system
KR101257783B1 (en) * 2011-07-07 2013-04-24 주식회사 인트로메딕 capsule endoscope
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8956287B2 (en) 2006-05-02 2015-02-17 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9060708B2 (en) 2008-03-05 2015-06-23 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9083589B2 (en) 2006-11-20 2015-07-14 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US9119918B2 (en) 2009-03-25 2015-09-01 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US9149577B2 (en) 2008-12-15 2015-10-06 Proteus Digital Health, Inc. Body-associated receiver and method
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9320455B2 (en) 2009-04-28 2016-04-26 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
JP2016144696A (en) * 2005-09-01 2016-08-12 プロテウス デジタル ヘルス, インコーポレイテッド Implantable zero-wire communications system
US9415010B2 (en) 2008-08-13 2016-08-16 Proteus Digital Health, Inc. Ingestible circuitry
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038646B2 (en) 2004-10-15 2011-10-18 Olympus Corporation Body-insertable apparatus and manufacturing method thereof
JP2006110193A (en) * 2004-10-15 2006-04-27 Olympus Corp Introduction apparatus into patient, and production method therefor
US9439582B2 (en) 2005-04-28 2016-09-13 Proteus Digital Health, Inc. Communication system with remote activation
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
JP2012183385A (en) * 2005-04-28 2012-09-27 Proteus Biomedical Inc Pharma-informatics system
US9119554B2 (en) 2005-04-28 2015-09-01 Proteus Digital Health, Inc. Pharma-informatics system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
JP2016144696A (en) * 2005-09-01 2016-08-12 プロテウス デジタル ヘルス, インコーポレイテッド Implantable zero-wire communications system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8956287B2 (en) 2006-05-02 2015-02-17 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US9444503B2 (en) 2006-11-20 2016-09-13 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9083589B2 (en) 2006-11-20 2015-07-14 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9878094B2 (en) 2006-11-21 2018-01-30 Stoco 10 GmbH Medicament delivery device, capsule and in vivo medicine delivery or diagnostic system
JP2010509969A (en) * 2006-11-21 2010-04-02 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Drug delivery devices, capsules, and drug delivery or diagnostic system for invivo
US8858432B2 (en) 2007-02-01 2014-10-14 Proteus Digital Health, Inc. Ingestible event marker systems
JP2010524512A (en) * 2007-02-01 2010-07-22 プロテウス バイオメディカル インコーポレイテッド Ingestible event marker system
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
JP2008280461A (en) * 2007-05-11 2008-11-20 Kagoshima Univ Liquid crystal gel, heat drive unit, and method for producing liquid crystal gel
US9433371B2 (en) 2007-09-25 2016-09-06 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US9258035B2 (en) 2008-03-05 2016-02-09 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9060708B2 (en) 2008-03-05 2015-06-23 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9415010B2 (en) 2008-08-13 2016-08-16 Proteus Digital Health, Inc. Ingestible circuitry
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9149577B2 (en) 2008-12-15 2015-10-06 Proteus Digital Health, Inc. Body-associated receiver and method
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9119918B2 (en) 2009-03-25 2015-09-01 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US9320455B2 (en) 2009-04-28 2016-04-26 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
KR101257783B1 (en) * 2011-07-07 2013-04-24 주식회사 인트로메딕 capsule endoscope
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10097388B2 (en) 2013-09-20 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers

Similar Documents

Publication Publication Date Title
JP5460538B2 (en) The methods and methods of using the system to produce transdermal drug delivery patch system, the system
EP1919379B1 (en) Cannula for sealing a gastric opening
US7931694B2 (en) Stomach peristalsis device and method
JP4738806B2 (en) Mechanically adjustable gastric band
CA2554316C (en) Electroactive polymer-based pump
US8052711B2 (en) Method and apparatus for fixating an implantable medical device
AU2008296110B2 (en) Device for intermittently obstructing a gastric opening and method of use
US6287294B1 (en) Medical devices using electrosensitive gels
ES2672997T3 (en) Gastrointestinal devices stimulation
KR100482275B1 (en) Micro capsule robot
US20170181878A1 (en) Methods and devices to curb appetite and/or to reduce food intake
US9504785B2 (en) Implantable infusion devices and methods
US20170050005A1 (en) Swallowable drug delivery device and methods of drug delivery
US20120253378A1 (en) Devices and Methods for Treatment of Obesity
JP4660590B2 (en) Capsule microrobot driving system
US20070156248A1 (en) Bioerodible self-deployable intragastric implants
US20020128692A1 (en) Hermetically sealed feedthrough connector using shape memory alloy for implantable medical device
US20040267240A1 (en) Active drug delivery in the gastrointestinal tract
EP2101643B1 (en) Design of swallowable multi-nozzle, dosing device for releasing medicines in the gastrointestinal tract
US20080063703A1 (en) Active Drug Delivery in the Gastrointestinal Tract
CA2646134C (en) Extragastric implantable devices for treatment of obesity
US20070255336A1 (en) Gastric constriction device with selectable electrode combinations
US8734429B2 (en) Device, system and methods for the oral delivery of therapeutic compounds
US20060079944A1 (en) Device and method for treating obesity
US7920921B2 (en) Endoscopic device delivery system

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 19990518